Prostate cancer (PCa) is a prevalent malignancy that occurs primarily in old males. Prostate
tumors in different patients manifest significant inter-patient heterogeneity with respect to …

Solid tumors can be divided into benign solid tumors and solid malignant tumors in the
academic community, among which malignant solid tumors are called cancers. Cancer is …

Heterogeneous response to Enzalutamide, a second-generation androgen receptor
signaling inhibitor, is a central problem in castration-resistant prostate cancer (CRPC) …

Background Prostate cancer is a major cause of cancer morbidity and mortality in men
worldwide. Androgen deprivation therapy (ADT) has proven effective in early-stage …

Tumor heterogeneity plays a key role in prostate cancer prognosis, therapy selection,
relapse, and acquisition of treatment resistance. Prostate cancer presents a heterogeneous …

Cancer progression is characterized and driven by gradual loss of a differentiated
phenotype and gain of stem cell-like features. In prostate cancer (PCa), androgen receptor …

Despite decades of research and successful improvements in diagnosis and therapy,
prostate cancer (PC) remains a major challenge. In recent years, it has become clear that …

Simple Summary Castration-resistant prostate cancer (CRPC) is an advanced form of
prostate cancer with a low survival rate, as the CRPC patients only survive for 9–13 months …

Prostate cancer is one of the most often diagnosed malignancies in males and its
prevalence is rising in both developed and developing countries. Androgen deprivation …

In this study, we examined the metabolic adaptations of a chemoresistant prostate cancer
cell line in comparison to a sensitive cell line. We utilized prostate cancer LNCaP cells and …